title: When should F-18 FDG PET/CT be used instead of 68Ga-DOTA-peptides to investigate metastatic neuroendocrine tumors?
authors: Department of Nuclear Medicine, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
authors: Chiara
authors: C
authors: Fuccio
authors: Alessandra
authors: A
authors: Musto
authors: Silvia
authors: S
authors: Cambioli
authors: Paolo
authors: P
authors: Castellucci
authors: Maria A
authors: MA
authors: Pantaleo
authors: Cristina
authors: C
authors: Nanni
authors: Gian C
authors: GC
authors: Montini
authors: Davide
authors: D
authors: Campana
authors: Paolo
authors: P
authors: Tomassetti
authors: Elena
authors: E
authors: Bellan
authors: Arianna
authors: A
authors: Massaro
authors: Gaia
authors: G
authors: Grassetto
authors: Domenico
authors: D
authors: Rubello
authors: Stefano
authors: S
authors: Fanti
mesh_terms: D000368:Aged; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008099:Liver / Q000000981:diagnostic imaging; D008297:Male; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000473:pathology; D009942:Organometallic Compounds; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed
chemical_list: C504894:68Ga-DOTANOC; D009942:Organometallic Compounds; D019788:Fluorodeoxyglucose F18